The ACER1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from A-549 lung epithelial cells, in which the alkaline ceramidase 1 (ACER1) gene has been disrupted to generate a loss-of-function model. This polyclonal pool provides a heterogeneous yet potent tool for investigating ceramide metabolism and its downstream signaling consequences without the clonal selection biases inherent in single-cell-derived lines.
The A-549 host cell line originates from the lung adenocarcinoma of a 58-year-old Caucasian male and serves as a well-established model of human alveolar type II pulmonary epithelium. These adherent epithelial cells retain key characteristics of type II pneumocytes, including surfactant production and metabolic activity, making them widely employed in respiratory disease research and cancer biology.
ACER1 encodes an alkaline ceramidase that hydrolyzes very long chain ceramides to sphingosine, which is subsequently phosphorylated by sphingosine kinases SPHK1 and SPHK2 to generate sphingosine-1-phosphate (S1P), a bioactive lipid that promotes cell survival and proliferation through S1P receptors (S1PR1-5). This reaction counteracts ceramide-mediated apoptosis, positioning ACER1 at a critical regulatory node in sphingolipid metabolism. Upstream, ACER1 expression is modulated by transcription factor p53, tumor necrosis factor ?? (TNF??), and all-trans retinoic acid, linking it to DNA damage responses and inflammatory signals. The enzyme functionally interacts with ceramide synthases that provision its substrate and sphingosine-1-phosphate phosphatases that dephosphorylate S1P, integrating multiple metabolic inputs.
In A-549 adenocarcinoma cells, ACER1 disruption leads to accumulation of ceramide species and reduced S1P production, shifting the equilibrium toward pro-apoptotic signaling and attenuating tumorigenic potential. This knockout model enables dissection of how ceramide/S1P balance influences alveolar epithelial carcinogenesis, drug sensitivity, and resistance mechanisms. It provides a physiologically relevant backdrop for evaluating the interplay between sphingolipid metabolism and oncogenic pathways in a clinically pertinent cell type.
Research applications encompass lung adenocarcinoma biology, ceramide-dependent apoptosis signaling, and screening of alkaline ceramidase inhibitors. The polyclonal population supports quantitative ceramide profiling via LC-MS, S1P ELISA monitoring, Annexin V/propidium iodide apoptosis assays, and functional studies using MTT viability or sphingosine kinase activity measurements. RT-qPCR analysis of sphingolipid pathway genes and flow cytometric cell cycle assessment further expand the model??s utility in pharmacological and genetic investigations. For additional details or technical inquiries, please contact Ascent Research.
